Clinical Trial Update: Bridging Study With GSK239512 In Patients With Mild To Moderate Alzheimer's Disease [Phase 1]

View source ↗

Summary

A bridging Phase 1 study of GSK239512 in patients with Alzheimer's disease has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Alzheimer Disease

Drugs mentioned

• GSK239512 (GSK239512)

Snippet

Sponsor: GlaxoSmithKline | Conditions: Alzheimer's Disease | Phase 1 | Status: COMPLETED